Literature DB >> 32060110

Very unusual case of a primary sinonasal germ cell tumour.

Katie Ann Sadler1,2, Catherine Hanna2,3, Louise Melia4, Jeff White5.   

Abstract

Sinonasal malignancies are a very rare diagnosis. We present a unique case of a 32-year-old man who presented with symptoms of worsening sinusitis and periorbital cellulitis. Investigation found a sinonasal malignancy and pathology confirmed this to be a primary germ cell tumour. The patient was managed with chemotherapy, surgery and consolidation radiotherapy and has remained well to date. This case report outlines an unusual presentation and diagnostic challenge for the primary care physician, ear, nose and throat surgeon, pathologist and oncologist with review of the surrounding literature. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ear, nose and throat/otolaryngology; head and neck cancer; oncology; pathology

Mesh:

Year:  2020        PMID: 32060110      PMCID: PMC7046431          DOI: 10.1136/bcr-2019-232288

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  20 in total

Review 1.  Radiation dose-volume effects of optic nerves and chiasm.

Authors:  Charles Mayo; Mary K Martel; Lawrence B Marks; John Flickinger; Jiho Nam; John Kirkpatrick
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 2.  A whiff of trouble: tumours of the nasal cavity and their mimics.

Authors:  M J Szewczyk-Bieda; R D White; M J Budak; G Ananthakrishnan; J N Brunton; T A Sudarshan
Journal:  Clin Radiol       Date:  2014-02-11       Impact factor: 2.350

3.  Tumors and tumor-like conditions of the nasal cavity, paranasal sinuses, and nasopharynx: A study of 206 cases.

Authors:  R N Satarkar; S Srikanth
Journal:  Indian J Cancer       Date:  2016 Oct-Dec       Impact factor: 1.224

4.  Relationship between 18FDG-PET and different types of sinonasal malignancies.

Authors:  Marylisa Felix-Ravelo; Ayoub Bey; Fabien Arous; Solène Paris-Grandpierre; Roger Jankowski; Duc Trung Nguyen
Journal:  Acta Otolaryngol       Date:  2016-08-31       Impact factor: 1.494

Review 5.  Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances.

Authors:  José Luis Llorente; Fernando López; Carlos Suárez; Mario A Hermsen
Journal:  Nat Rev Clin Oncol       Date:  2014-06-17       Impact factor: 66.675

6.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.

Authors:  S D Williams; R Birch; L H Einhorn; L Irwin; F A Greco; P J Loehrer
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

Review 7.  Imaging of sinonasal tumours.

Authors:  Heidi B Eggesbø
Journal:  Cancer Imaging       Date:  2012-05-07       Impact factor: 3.909

8.  Hamartomas, teratomas and teratocarcinosarcomas of the head and neck: Report of 3 new cases with clinico-pathologic correlation, cytogenetic analysis, and review of the literature.

Authors:  Semir Vranic; Samuel K Caughron; Slavisa Djuricic; Nurija Bilalovic; Sadiq Zaman; Ismet Suljevic; William M Lydiatt; Jane Emanuel; Zoran Gatalica
Journal:  BMC Ear Nose Throat Disord       Date:  2008-11-24

9.  Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer.

Authors:  R de Wit; G Stoter; D T Sleijfer; J P Neijt; W W ten Bokkel Huinink; L de Prijck; L Collette; R Sylvester
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

10.  A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).

Authors:  Robert A Huddart; Rhian Gabe; Fay H Cafferty; Philip Pollock; Jeff D White; Jonathan Shamash; Michael H Cullen; Sally P Stenning
Journal:  Eur Urol       Date:  2014-07-04       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.